Search for content, post, videos

Nanoform launches technology for biologics

lab

Nanoform Finland has announced a technology that can form biological nanoparticles as small as 50 nm and announced a new near-term business target for 2021 to deliver its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner.

As drug molecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market, states the company. The technology is in its early stages of development and a patent application has recently been filed with the US Patent Office for the technology. As of today, Nanoform has two non-GMP lines on the biologics side in addition to the eight CESS small molecule nanoparticle technology non-GMP lines.

“Small is powerful, also in Bio! We are committed to improving patients’ lives and supporting our pharmaceutical partners in developing the best medicines possible. Having established our CESS small molecule nanoparticle technology to GMP, we continue to focus on delivering value for our partners and now we can extend our partnerships into supporting their biological programs. There are significant challenges in drug development in this space and we look forward to working closely with pharma and biotech partners to discover how we can add value to their programs, provide patient benefit and competitive product differentiation,” says Edward Haeggstrom, Nanoform CEO.

Photo: iStock